$5.95akadawson-m Member Level Re: $5.95akadaws
Post# of 153167
(Total Views: 428)
Posted On: 05/17/2025 8:46:29 AM
$5.95akadawson-m
Member Level
Re: $5.95akadawson-m post# 235250
Saturday, May 17, 2025 8:12:10 AM
Post#
235252
of 235253
Lastly - in a week of very good news and anyone who is still invested in this stock is crazy like me but I assure you when people like Welch and now CYDY's SVP of
Clinical Development writes this in an open forum, yesterday, something is UP. I quote verbatim:
"Turning Cold Tumors Hot: Leronlimab’s Transformative Potential in TNBC"
At the recent ESMO 2025 Breast Cancer Meeting, my colleagues at CytoDyn Inc., @Jay Lalezari and @Richard Pestell, presented compelling retrospective data on 28 patients with metastatic triple-negative breast cancer (mTNBC) treated with Leronlimab. While this analysis is based on a small cohort, the findings offer promising insights that have sparked cautious optimism within the oncology community:
· PD-L1 Upregulation: 88% of patients treated with Leronlimab at doses ≥525 mg exhibited PD-L1 upregulation, potentially converting "cold" tumors into ICI-responsive "hot" tumors. This breakthrough is based on a novel serum assay capable of measuring PD-L1 upregulation in circulating tumor cells (CTCs), and cancer-associated macrophage-like cells (CAMLs) in peripheral blood.
· Long-Term Survival: 100% (5/5) of patients with significant PD-L1 upregulation who received Leronlimab combined with immune checkpoint inhibitors (ICIs) are alive at 48 months, with 80% (4/5) showing no evidence of disease (NED).
· Encouraging Survival in Late-Line Setting: The 3-4 year survival rate of 17.9% in this heavily pretreated, 4th-line patient population is significantly better than historical expectations.
· Favorable Safety Profile: No dose-limiting toxicities or treatment-related discontinuations were observed, a notable advantage in this patient population.
These results underscore Leronlimab’s potential as a first-in-class CCR5 inhibitor with both direct anti-tumor and immunomodulatory effects, reshaping the tumor microenvironment to render traditionally "cold" tumors more responsive to immunotherapy.
Prospectively confirming these findings in TNBC patients is a critical next step, and an important priority for CytoDyn as we continue to explore the transformative potential of Leronlimab in oncology.
Member Level
Re: $5.95akadawson-m post# 235250
Saturday, May 17, 2025 8:12:10 AM
Post#
235252
of 235253
Lastly - in a week of very good news and anyone who is still invested in this stock is crazy like me but I assure you when people like Welch and now CYDY's SVP of
Clinical Development writes this in an open forum, yesterday, something is UP. I quote verbatim:
"Turning Cold Tumors Hot: Leronlimab’s Transformative Potential in TNBC"
At the recent ESMO 2025 Breast Cancer Meeting, my colleagues at CytoDyn Inc., @Jay Lalezari and @Richard Pestell, presented compelling retrospective data on 28 patients with metastatic triple-negative breast cancer (mTNBC) treated with Leronlimab. While this analysis is based on a small cohort, the findings offer promising insights that have sparked cautious optimism within the oncology community:
· PD-L1 Upregulation: 88% of patients treated with Leronlimab at doses ≥525 mg exhibited PD-L1 upregulation, potentially converting "cold" tumors into ICI-responsive "hot" tumors. This breakthrough is based on a novel serum assay capable of measuring PD-L1 upregulation in circulating tumor cells (CTCs), and cancer-associated macrophage-like cells (CAMLs) in peripheral blood.
· Long-Term Survival: 100% (5/5) of patients with significant PD-L1 upregulation who received Leronlimab combined with immune checkpoint inhibitors (ICIs) are alive at 48 months, with 80% (4/5) showing no evidence of disease (NED).
· Encouraging Survival in Late-Line Setting: The 3-4 year survival rate of 17.9% in this heavily pretreated, 4th-line patient population is significantly better than historical expectations.
· Favorable Safety Profile: No dose-limiting toxicities or treatment-related discontinuations were observed, a notable advantage in this patient population.
These results underscore Leronlimab’s potential as a first-in-class CCR5 inhibitor with both direct anti-tumor and immunomodulatory effects, reshaping the tumor microenvironment to render traditionally "cold" tumors more responsive to immunotherapy.
Prospectively confirming these findings in TNBC patients is a critical next step, and an important priority for CytoDyn as we continue to explore the transformative potential of Leronlimab in oncology.
(11)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼